Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,647 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,647 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00424138 | FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy(ACRIN6678) | N/A | terminated | Jan 18, 2007 | American College of Radiology Imaging Network | Recruitment obstacles; data to be combined with other resources for analysis | Enrollment / accrual |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus… | Phase 2 | withdrawn | May 5, 2016 | Bristol-Myers Squibb | Insufficient enrollment | Enrollment / accrual |
| NCT02500914 | SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma | Phase 1 | terminated | Jul 17, 2015 | Stemcentrx | Strategic Considerations | Sponsor / business decision |
| NCT02580708 | Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib… | Phase 1 / Phase 2 | terminated | Oct 20, 2015 | Clovis Oncology, Inc. | Discontinued development of rociletinib in NSCLC. Stopped enrollment of new patients into all… | Enrollment / accrual |
| NCT02688907 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer… | Phase 2 | terminated | Feb 23, 2016 | Samsung Medical Center | change regimen | Other (stated, no rule matched) |
| NCT03106155 | Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring…([SUKSES-D]) | Phase 2 | terminated | Apr 10, 2017 | Samsung Medical Center | Decision of IP support organization | Other (stated, no rule matched) |
| NCT00260598 | LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer | Phase 2 | terminated | Dec 1, 2005 | University of Pittsburgh | LIFE Bronchoscopy equipment no longer functioning and cannot be repaired. | Other (stated, no rule matched) |
| NCT00352950 | Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer | Phase 1 | withdrawn | Jul 17, 2006 | Amgen | not stated | Not stated |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT02055170 | Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer | Phase 2 | terminated | Feb 5, 2014 | CancerCare Manitoba | Unable to improve on poor accrual to study. | Enrollment / accrual |
| NCT01058759 | Taxotere-Enoxaparin-(ENOXA)-Study | Phase 3 | terminated | Jan 29, 2010 | Hannover Medical School | The external funding (pharmaceutical company) was stopped and could not be substituded by internal… | Funding |
| NCT02672358 | Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese… | Phase 2 | withdrawn | Feb 3, 2016 | Novartis Pharmaceuticals | Company Decision | Sponsor / business decision |
| NCT02694380 | Measuring the Effect of Radiation Therapy on Patient Activity Levels | — | terminated | Feb 29, 2016 | University of Pittsburgh | Low accrual | Enrollment / accrual |
| NCT00748163 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line… | Phase 2 | withdrawn | Sep 8, 2008 | Masonic Cancer Center, University of Minnesota | Study has been abandoned for lack of available funding. | Funding |
| NCT00200382 | Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung… | Phase 2 | terminated | Sep 20, 2005 | Rasim Gucalp | The study did not achieve the statistical success to continue. | Other (stated, no rule matched) |
| NCT01028612 | Thermal Ablation Combined With External Beam Radiation Therapy for Patients With…(NSCLC) | N/A | terminated | Dec 9, 2009 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT03370159 | CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung… | Phase 1 / Phase 2 | withdrawn | Dec 12, 2017 | Wake Forest University Health Sciences | Sponsor decided not to move forward | Sponsor / business decision |
| NCT01935947 | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced… | Phase 2 | terminated | Sep 5, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00953459 | Sunitinib Malate in Treating Patients With Small Cell Lung Cancer | Phase 2 | terminated | Aug 6, 2009 | European Organisation for Research and Treatment of Cancer - EORTC | poorly recruiting | Enrollment / accrual |
| NCT03240393 | Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced… | Phase 2 | withdrawn | Aug 7, 2017 | Novartis Pharmaceuticals | Company Decision | Sponsor / business decision |
| NCT01041781 | Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without… | Phase 3 | terminated | Jan 1, 2010 | Alliance for Clinical Trials in Oncology | DSMB recommendation | Other (stated, no rule matched) |
| NCT02671045 | Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer | — | terminated | Feb 2, 2016 | Cota Inc. | Insufficient accrual to Horizon Bluecross Blueshield cohort | Enrollment / accrual |
| NCT03073473 | Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers | — | terminated | Mar 8, 2017 | Cota Inc. | Poor accrual | Enrollment / accrual |
| NCT02067858 | An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small… | N/A | terminated | Feb 20, 2014 | Steven Burton | slow accrual | Enrollment / accrual |
| NCT01208064 | Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer… | Phase 2 / Phase 3 | terminated | Sep 23, 2010 | European Organisation for Research and Treatment of Cancer - EORTC | based on IDMC decision | Other (stated, no rule matched) |
| NCT01610544 | 18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma | Phase 2 | withdrawn | Jun 4, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02011087 | Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With… | N/A | terminated | Dec 13, 2013 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT02014545 | Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain… | Phase 2 | withdrawn | Dec 18, 2013 | Wake Forest University Health Sciences | Pending resolution of study drug issues | Other (stated, no rule matched) |
| NCT01325753 | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or… | N/A | withdrawn | Mar 30, 2011 | Wake Forest University Health Sciences | not stated | Not stated |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Phase 1 / Phase 2 | terminated | Jan 6, 2015 | Western Regional Medical Center | PI not longer at site. | Other (stated, no rule matched) |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | Phase 1 / Phase 2 | terminated | Apr 22, 2015 | Western Regional Medical Center | Investigator no longer at site to enroll patients or write up data | Investigator |
| NCT02566421 | Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer… | N/A | terminated | Oct 2, 2015 | Wake Forest University Health Sciences | Assessing Feasibility | Other (stated, no rule matched) |
| NCT02748889 | Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small… | Phase 1 / Phase 2 | terminated | Apr 22, 2016 | Giuseppe Giaccone | Difficulties with recruitment | Enrollment / accrual |
| NCT01789892 | Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in… | N/A | withdrawn | Feb 12, 2013 | Ohio State University Comprehensive Cancer Center | no patient accrual | Enrollment / accrual |
| NCT02161419 | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer(CONCEPT-SCLC) | Phase 2 | terminated | Jun 11, 2014 | Bayer | not stated | Not stated |
| NCT01159964 | Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer,… | Phase 1 | terminated | Jul 12, 2010 | GlaxoSmithKline | Study termination due to negative Phase III of another study product from same technology platform. | Other (stated, no rule matched) |
| NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients… | Phase 2 | terminated | Aug 10, 2009 | National Cancer Institute (NCI) | The study was closed to accrual due to the end of the clinical development program with cixutumumab. | Enrollment / accrual |
| NCT02252796 | Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer(HySBst) | Phase 1 | terminated | Sep 30, 2014 | West Virginia University | Investigator left institution | Investigator |
| NCT01987193 | Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation… | — | terminated | Nov 19, 2013 | University of Florida | Slow accrual; funding stopped | Enrollment / accrual |
| NCT02250404 | Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung… | — | withdrawn | Sep 26, 2014 | University of Southern California | PI left institution | Investigator |
| NCT03051802 | Feasibility Study of Navigated Endoscopy for the Placement of High Dose Rate… | N/A | terminated | Feb 14, 2017 | University Health Network, Toronto | Slow recruitment | Enrollment / accrual |
| NCT01607554 | Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | May 30, 2012 | New Mexico Cancer Research Alliance | Inadequate enrollment (2 subjects in 4 years) | Enrollment / accrual |
| NCT01117714 | Surgical Versus Non-surgical Staging of Lung Cancer | N/A | terminated | May 5, 2010 | Medical University of South Carolina | Accrual was poor at two other sites and manuscript was published which describing another study… | Enrollment / accrual |
| NCT02423148 | Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in… | N/A | withdrawn | Apr 22, 2015 | Dana-Farber Cancer Institute | Co-investigator left facility. Decided not to enroll patients therefore. | Investigator |
| NCT03216863 | Home Respiratory Rehabilitation in Advanced Lung Cancer Chemotherapy Per os | N/A | terminated | Jul 13, 2017 | University Hospital, Lille | not stated | Not stated |
| NCT00852644 | Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell… | N/A | terminated | Feb 27, 2009 | Boston Medical Center | poor accrual | Enrollment / accrual |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | terminated | Sep 7, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT03417037 | An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With… | Phase 3 | withdrawn | Jan 31, 2018 | Bristol-Myers Squibb | Business objectives have changed. | Sponsor / business decision |
| NCT03023904 | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation… | Phase 2 | withdrawn | Jan 18, 2017 | Vanderbilt-Ingram Cancer Center | Research cancelled | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 11, 2018source: clinicaltrials